title: Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.
abstract: OBJECTIVE
  The main goal of the present study was the evaluation of ischemia-modified albumin (IMA) in patients with type 2 diabetes mellitus and estimation of its connection with vascular complications, glycemic control, hypertension, dyslipidemia and obesity.
  
  
  METHODS
  In 76 diabetic patients and 25 control subjects, a plasma level of IMA by manually performed, spectrophotometric Co(II)-albumin binding assay was determined. Other parameters such as glucose, fructosamine, HbA_{1c}, total cholesterol and its fractions (HDL, LDL), triglicerydes were estimated by routine methods.
  
  
  RESULTS
  Diabetic patients had significantly higher level of IMA in comparison with control subjects. There were not significant differences between groups with various states of vascular complications although the lowest concentration of IMA was observed in patients with microangiopathy. Patients with poor glycemic control had higher IMA level in comparison with these with good glycemic control. Significant correlation was observed between IMA and HbA_{1c}. Among the risk factors, only blood pressure and LDL showed a weak relationship with IMA level.
  
  
  CONCLUSIONS
  Our results revealed, for the first time, higher level of IMA in diabetic patients which confirms that it may be of non-cardiac origin. We can suggest that the albumin molecule in plasma of diabetic patients is modified in the chronic hypoxia conditions provoked mainly by hyperglycemia and oxidative stress in diabetes.
authors.affiliation: Department of Pharmaceutical Biochemistry of Wroclaw Medical University, Wrocław, Poland. piwowar@biochfarm.am.wroc.pl
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Piwowar
authors.forename: Maria
authors.initials: M
authors.lastname: Knapik-Kordecka
authors.forename: Maria
authors.initials: M
authors.lastname: Warwas
mesh_terms: D015415:Biomarkers / Q000097:blood*; D001786:Blood Glucose; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003925:Diabetic Angiopathies / Q000097:blood / Q000150:complications; D003930:Diabetic Retinopathy / Q000097:blood / Q000150:complications; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D007511:Ischemia / Q000097:blood*; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications; D018384:Oxidative Stress; D012709:Serum Albumin / Q000378:metabolism*; D014652:Vascular Diseases / Q000097:blood / Q000150:complications
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D008055:Lipids; D012709:Serum Albumin